ArticleOphthalmology science2026
Topographically Resolved Macular Pigment Optical Density Is Associated with Disease Progression in Macular Telangiectasia Type 2.
Article in Ophthalmology science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate differences in topographically resolved macular pigment optical density (MPOD) between macular telangiectasia type 2 (MacTel) stages and to analyze its association with disease progression. Design: Longitudinal cohort study. Subjects: Participants of the Natural History and Observation Registry study and the University Eye Hospital in Bonn. Methods: Participants underwent multimodal retinal imaging including spectral-domain OCT, two-wavelength autofluorescence (2WAF) imaging for MPOD, and color fundus photography. Disease stage (0-6) was graded according to Chew et al. Macular pigment optical density en face maps were generated from 2WAF images, aligned to the fovea, and averaged within ETDRS subfields. Spatial differences across stages were assessed using linear mixed-effects models. Progression was defined as stage increase during follow-up and analyzed using univariable and multivariable regression models to estimate odds ratios for progression. Main Outcome Measures: Differences in topographically resolved MPOD, and association with disease progression. Results: A total of 265 eyes from 220 patients with MacTel (mean age 62.6 ± 7.7 years; 60.5% female) were analyzed. Eyes were staged as follows: stage 0 (38 eyes), stage 1 (45), stage 2 (67), stage 3 (12), stage 4 (24), stage 5 (46), and stage 6 (33). En face maps demonstrated stage-dependent alterations in MPOD: early temporal depletion and a preserved nasal-inferior bridge of MP in stages 1 to 4, followed by progressive central and nasal loss and attenuation of the parafoveal ring. Macular pigment optical density differed significantly across stages in the central and inner ETDRS subfields (all Conclusions: Macular pigment optical density maps reveal spatial alterations in MacTel and demonstrate the likelihood of progress of quantitative MPOD measurements. These findings may help identify eyes that could benefit from early neuroprotective interventions before irreversible vision loss occurs. Financial Disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.